09:18 AM EDT, 06/02/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) said Monday that the results from its phase 1 study of KT-621 showed complete STAT6 degradation in both blood and skin, demonstrating a potential to treat Th2 diseases such as atopic dermatitis.

The drug was well tolerated with a safety profile undifferentiated from placebo, with no serious adverse events in the trial and no treatment related adverse events in more than one patient, Kymera said.

The company said it is actively recruiting participants for its phase 1b trial in moderate to severe atopic dermatitis and expects data in Q4.

Kymera said it plans two parallel phase 2b trials in atopic dermatitis and asthma for Q4 and Q1 of 2026, respectively, intended to accelerate KT-621 development and enable dose selection for subsequent parallel phase 3 registration studies.

Shares were up over 37% in recent premarket activity.